Abstract:Dysregulation of the extracellular matrix (ECM) properties disturbs tissue homeostasis and contributes to pathological conditions, such as cancer. Recent studies have demonstrated that ECM stiffening is associated with metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. This underscores a compelling need to develop a physiologically-relevant 3D culture model to enable the study of the independent contribution of matrix stiffness to the initiation and progression of esophageal adenocarcinoma (EAC). Such a model will then serve as a platform for pre-clinical drug screening in the context of matrix properties. In this context, we have engineered a hyaluronic acid-based 3D hydrogel platform that supports the growth and differentiation of patient-derived Barrett's esophagus (BE) organoids, a precursor to EAC, as well as patient-derived EAC organoids. The engineered biomaterial 3D platform allows control over matrix stiffness to better recapitulate the mechanically dynamic esophageal cancer microenvironment and help identify therapeutic targets in EAC.Our data demonstrates that BE and EAC organoid density, growth and proliferation can be controlled by matrix stiffness. RNA sequencing data show that increased matrix stiffness promotes changes in the transcriptional profiles of BE and EAC organoids, revealing enrichment of pathways associated with tumorigenesis and disease progression. Furthermore, we demonstrate through molecular and functional assays that increased matrix stiffness endows stem-like properties to the EAC organoids via Yap-Sox9 mechano-activation. Finally, targeted therapy studies in our in vitro and in vivo engineered environments revealed that Yap inhibition regressed the effects of increased matrix stiffness in EAC organoids. In summary, our data suggest that matrix mechanics have a significant role in activation of EAC-associated signaling pathways in patient-derived BE and EAC organoids. We also demonstrate that the engineered hydrogel serves as a platform to identify potential therapeutic targets to disrupt the contribution of pro-tumorigenic matrix mechanics in EAC. Together, these studies establish an engineered patient-derived organoid culture platform that can be used to elucidate underlying matrix-mediated mechanisms of the metaplasia-dysplasia-adenocarcinoma sequence and inform the development of novel therapeutics that target ECM stiffness in EAC. FUNDING SOURCES: NCI P01CA098101, U54 CA163004 and NIDDK K01 DK133620. Citation Format: Ricardo Cruz-Acuna, Secunda W. Kariuki, Kensuke Sugiura, Spyros Karaiskos, Eleanor M. Plaster, Claudia Loebel, Gizem Efe, Tatiana Karakasheva, Joel T. Gabre, Jianhua Hu, Jason A. Burdick, Anil K. Rustgi. Engineered hydrogel elucidates contributions of matrix mechanics to pathobiology of adenocarcinoma and identify matrix-activated therapeutic targets [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4268.

Transformable ECM Deprivation System Effectively Suppresses Renal Cell Carcinoma by Reversing Anoikis Resistance and Increasing Chemotherapy Sensitivity (Adv. Mater. 43/2022)

Modulating Tumor Extracellular Matrix by Simultaneous Inhibition of Two Cancer Cell Receptors.

Safe Engineering of Cancer-Associated Fibroblasts Enhances Checkpoint Blockade Immunotherapy.

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

Transformable Dual‐Inhibition System Effectively Suppresses Renal Cancer Metastasis through Blocking Endothelial Cells and Cancer Stem Cells

Cancer Therapy: Transformable Dual‐Inhibition System Effectively Suppresses Renal Cancer Metastasis through Blocking Endothelial Cells and Cancer Stem Cells (Small 40/2020)

Biomimetic Hydrogel‐Mediated Mechano‐Immunometabolic Therapy for Inhibition of ccRCC Recurrence After Surgery

Extracellular Matrix Viscosity Reprogramming by in Situ Au Bioreactor-Boosted Microwavegenetics Disables Tumor Escape in CAR-T Immunotherapy.

Gene Editing of the Extra Domain A Positive Fibronectin in Various Tumors, Amplified the Effects of CRISPR/Cas System on the Inhibition of Tumor Progression.

Erythrocyte Membrane Camouflaged Metal–Organic Framework Nanodrugs for Remodeled Tumor Microenvironment and Enhanced Tumor Chemotherapy

Enhanced Tumor Site Accumulation and Therapeutic Efficacy of Extracellular Matrix‐Drug Conjugates Targeting Tumor Cells

Specific ECM degradation potentiates the antitumor activity of CAR-T cells in solid tumors

Therapeutic effects and underlying mechanism of poly (L-glutamic acid)-g-methoxy poly (ethylene glycol)/combretastatin A4/BLZ945 nanoparticles on Renca renal carcinoma

Tumor Extracellular Matrix-Targeted Nanoscavengers Reverse Suppressive Microenvironment for Cocktail Therapy

Boosting Clear Cell Renal Carcinoma-Specific Drug Discovery Using a Deep Learning Algorithm and Single-Cell Analysis

Abstract 533: Attenuating EZH2-mediated metastasis and tumor growth by pharmacological-based approaches using three-dimensional in vitro culture models

Enhancement Structural and Signaling Microenvironment of Artificial Tumor Extracellular Matrix for Enhanced Drug Screening

Abstract 4268: Engineered hydrogel elucidates contributions of matrix mechanics to pathobiology of adenocarcinoma and identify matrix-activated therapeutic targets

Enhanced Intracellular Transcytosis of Nanoparticles by Degrading Extracellular Matrix for Deep Tissue Radiotherapy of Pancreatic Adenocarcinoma

Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors

Engineered hydrogel reveals contribution of matrix mechanics to esophageal adenocarcinoma and identifies matrix-activated therapeutic targets